• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Lupin Obtains Multiple Legacy Brands from Menarini


Deal comes amid previous exclusive marketing agreement.

Pharmaceutical entrepreneur foster global business growth and expansion through a robust network focused on acquiring new customers and strategic partnerships. Image Credit: Adobe Stock Images/Manoj

Image Credit: Adobe Stock Images/Manoj

Lupin revealed that it has inked an agreement with Menarini to acquire five of its legacy brands in strategic therapy. Including the areas of gastroenterology, urology, and anti-infectives, the brands are Piclin (Ppcosulphate sodium), Menoctyl (otilonium bromide), Sucramal O (sucralfate +oxetacaine), Pyridium (phenazopyridine) and Distaclor (cefaclor). The deal comes as Lupin has been exclusively marketing the brands in the Indian market since July 2021 under a distribution and promotion agreement.

“Growing urbanization and dietary changes are driving the demand for gastrointestinal and urology treatments in India,” said Rajeev Sibal, president, India region formulations, Lupin. “This acquisition strengthens our presence in India and bolsters our therapy pipeline. At Lupin, we are committed to empowering healthcare professionals in managing the increasing disease burden and improving the lives of patients significantly.”

Reference: Lupin Acquires Five Brands from Menarini. Lupin. September 22, 2023. Accessed September 25, 2023. https://www.lupin.com/lupin-acquires-five-brands-from-menarini/

Recent Videos
Related Content